Rivaroxaban attenuates thrombosis by targeting the NF-κB signaling pathway in a rat model of deep venous thrombus Retraction in /10.3892/ijmm.2018.3565

Ma,Junhao; Li,Xinxi; Wang,Yang; Yang,Zhenwei; Luo,Jun

doi:10.3892/ijmm.2017.3166

Rivaroxaban attenuates thrombosis by targeting the NF-κB signaling pathway in a rat model of deep venous thrombus

Retraction in: /10.3892/ijmm.2018.3565

Authors:
- Junhao Ma
- Xinxi Li
- Yang Wang
- Zhenwei Yang
- Jun Luo
View Affiliations

Affiliations: Department of Blood Vessels of Thyroid Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang 830000, P.R. China
Published online on: September 29, 2017 https://doi.org/10.3892/ijmm.2017.3166
Pages: 1869-1880
Copyright: © Ma et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anticoagulant therapy is commonly used for the prevention and treatment of patients with deep venous thrombus. Evidence has shown that rivaroxaban is a potential oral anticoagulant drug for the acute treatment of venous thromboembolism. However, the rivaroxaban-mediated molecular mechanism involved in the progression of deep venous thrombosis has not been investigated. In the present study, we investigated the efficacy of rivaroxaban and the underlying signaling pathways in the prevention and treatment of rats with deep venous thrombosis. A rat model with deep vein thrombus formation was established and received treatment with rivaroxaban or PBS as control. The thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 (PAI-1) were analyzed both in vitro and in vivo. The progression of thrombosis and stroke was evaluated after treatment with rivaroxaban or PBS. Nuclear factor-κB (NF-κB) signaling pathway in venous endothelial cells and in the rat model of deep venous thrombus was assessed. The therapeutic effects of rivaroxaban were evaluated as determined by changes in deep venous thrombosis in the rat model. Our results showed that rivaroxaban markedly inhibited TAFI and PAI-1 expression levels, neutrophils, tissue factor, neutrophil extracellular traps (NETs), myeloperoxidase and macrophages in venous endothelial cells and in the rat model of deep venous thrombus. Expression levels of ADP, PAIs, von Willebrand factor (vWF) and thromboxane were downregulated in vein endothelial cells and in serum from the experimental rats. Importantly, the incidences of inferior vena cava filter thrombus were protected by rivaroxaban during heparin-induced thrombolysis deep venous thrombosis in the rat model. We observed that activity of the NF-κB signaling pathway was inhibited by rivaroxaban in vein endothelial cells both in vitro and in vivo. Notably, immunohistology indicated that rivaroxaban attenuated deep venous thrombosis and the accumulation of inflammatory factors in the lesions in venous thrombus. Matrix metalloproteinase (MMP) expression and activity were downregulated in rivaroxaban-treated rats with deep venous thrombus. Rivaroxaban inhibited the elasticity of the extracellular matrix and collagen-elastin fibers. On the whole, these results indicate that rivaroxaban attenuates deep venous thrombus through MMP-9-mediated NF-κB signaling pathway.

View Figures

View References

1	Sharifi M, Bay C, Mehdipour M and Sharifi J; TORPEDO Investigators: Thrombus obliteration by rapid percutaneous endovenous intervention in deep venous occlusion (TORPEDO) trial: Midterm results. J Endovasc Ther. 19:273–280. 2012. View Article : Google Scholar : PubMed/NCBI
2	Meissner MH, Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, Lohr JM, McLafferty RB, Murad MH, Padberg F, et al Society for Vascular Surgery; American Venous Forum: Early thrombus removal strategies for acute deep venous thrombosis: Clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 55:1449–1462. 2012. View Article : Google Scholar : PubMed/NCBI
3	Santin BJ, Lohr JM, Panke TW, Neville PM, Felinski MM, Kuhn BA, Recht MH and Muck PE: Venous duplex and pathologic differences in thrombus characteristics between de novo deep vein thrombi and endovenous heat-induced thrombi. J Vasc Surg Venous Lymphat Disord. 3:184–189. 2015. View Article : Google Scholar
4	Sevuk U, Altindag R, Bahadir MV, Ay N, Demirtas E and Ayaz F: Value of platelet indices in identifying complete resolution of thrombus in deep venous thrombosis patients. Indian J Hematol Blood Transfus. 31:71–76. 2015. View Article : Google Scholar
5	Comerota AJ and Paolini D: Treatment of acute iliofemoral deep venous thrombosis: a strategy of thrombus removal. Eur J Vasc Endovasc Surg. 33:351–362. 2007. View Article : Google Scholar
6	Vucić N, Magdić T, Krnić A, Vcev A and Bozić D: Thrombus size is associated with etiology of deep venous thrombosis - a cross-sectional study. Coll Antropol. 29:643–647. 2005.
7	Kölbel T, Alhadad A, Acosta S, Lindh M, Ivancev K and Gottsäter A: Thrombus embolization into IVC filters during catheter-directed thrombolysis for proximal deep venous thrombosis. J Endovasc Ther. 15:605–613. 2008. View Article : Google Scholar : PubMed/NCBI
8	Aziz F and Comerota AJ: Quantity of residual thrombus after successful catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with recurrence. Eur J Vasc Endovasc Surg. 44:210–213. 2012. View Article : Google Scholar : PubMed/NCBI
9	Dong DN, Wu XJ, Zhang SY, Zhong ZY and Jin X: Clinical analysis of patients with lower extremity deep venous thrombosis complicated with inferior vena cava thrombus. Zhonghua Yi Xue Za Zhi. 93:1611–1614. 2013.In Chinese. PubMed/NCBI
10	Shi J, Zhi P, Chen J, Wu P and Tan S: Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: A systematic review and meta-analysis. Thromb Res. 134:610–616. 2014. View Article : Google Scholar : PubMed/NCBI
11	Bavbek N, Ceri M, Akdeniz D, Kargili A, Duranay M, Erdemli K, Akcay A and Guz G: Higher thrombin activatable fibrinolysis inhibitor levels are associated with inflammation in attack-free familial Mediterranean fever patients. Ren Fail. 36:743–747. 2014. View Article : Google Scholar : PubMed/NCBI
12	Sherif EM, Elbarbary NS, Abd Al Aziz MM and Mohamed SF: Plasma thrombin-activatable fibrinolysis inhibitor levels in children and adolescents with type 1 diabetes mellitus: possible relation to diabetic microvascular complications. Blood Coagul Fibrinolysis. 25:451–457. 2014. View Article : Google Scholar : PubMed/NCBI
13	Tsantes AE, Nikolopoulos GK, Bagos PG, Rapti E, Mantzios G, Kapsimali V and Travlou A: Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis. A meta-analysis. Thromb Haemost. 97:907–913. 2007.PubMed/NCBI
14	Dubis J, Zuk N, Grendziak R, Zapotoczny N, Pfanhauser M and Witkiewicz W: Activity of thrombin-activatable fibrinolysis inhibitor in the plasma of patients with abdominal aortic aneurysm. Blood Coagul Fibrinolysis. 25:226–231. 2014. View Article : Google Scholar : PubMed/NCBI
15	Naderi M, Dorgalaleh A, Alizadeh S, Kashani Khatib Z, Tabibian S, Kazemi A, Dargahi H and Bamedi T: Polymorphism of thrombin-activatable fibrinolysis inhibitor and risk of intra-cranial haemorrhage in factor XIII deficiency. Haemophilia. 20:e89–e92. 2014. View Article : Google Scholar
16	Plug T and Meijers JC: New clues regarding the mysterious mechanism of activated thrombin-activatable fibrinolysis inhibitor self-destruction. J Thromb Haemost. 13:1081–1083. 2015. View Article : Google Scholar : PubMed/NCBI
17	Oztuzcu S, Ergun S, Ulaşlı M, Nacarkahya G, Iğci YZ, Iğci M, Bayraktar R, Tamer A, Çakmak EA and Arslan A: Evaluation of Factor V G1691A, prothrombin G20210A, Factor XIII V34L, MTHFR A1298C, MTHFR C677T and PAI-1 4G/5G genotype frequencies of patients subjected to cardiovascular disease (CVD) panel in south-east region of Turkey. Mol Biol Rep. 41:3671–3676. 2014. View Article : Google Scholar : PubMed/NCBI
18	Hilbers FS, Boekel NB, van den Broek AJ, van Hien R, Cornelissen S, Aleman BM, van't Veer LJ, van Leeuwen FE and Schmidt MK: Genetic variants in TGFbeta-1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer. Radiother Oncol. 102:115–121. 2012. View Article : Google Scholar
19	Heineking B, Riebel T, Scheer I, Kulozik A, Hoehn T and Bührer C: Intraventricular hemorrhage in a full-term neonate associated with sinus venous thrombosis and homozygosity for the plasminogen activator inhibitor-1 4G/4G polymorphism. Pediatr Int. 45:93–96. 2003. View Article : Google Scholar : PubMed/NCBI
20	Lichy C, Kloss M, Reismann P, Genius J, Grau A and Reuner K: No evidence for plasminogen activator inhibitor 1 4G/4G genotype as risk factor for cerebral venous thrombosis. J Neurol. 254:1124–1125. 2007. View Article : Google Scholar : PubMed/NCBI
21	Ringelstein M, Jung A, Berger K, Stoll M, Madlener K, Klötzsch C, Schlachetzki F and Stolz E: Promotor polymorphisms of plasminogen activator inhibitor-1 and other thrombophilic genotypes in cerebral venous thrombosis: A case-control study in adults. J Neurol. 259:2287–2292. 2012. View Article : Google Scholar : PubMed/NCBI
22	Mutch NJ, Moore NR, Wang E and Booth NA: Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost. 1:2000–2007. 2003. View Article : Google Scholar : PubMed/NCBI
23	Zhai K, Tang Y, Zhang Y, Li F, Wang Y, Cao Z, Yu J, Kou J and Yu B: NMMHC IIA inhibition impedes tissue factor expression and venous thrombosis via Akt/GSK3β-NF-κB signalling pathways in the endothelium. Thromb Haemost. 114:173–185. 2015. View Article : Google Scholar : PubMed/NCBI
24	Li YD, Ye BQ, Zheng SX, Wang JT, Wang JG, Chen M, Liu JG, Pei XH, Wang LJ, Lin ZX, et al: NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis. J Biol Chem. 284:4473–4483. 2009. View Article : Google Scholar :
25	Hashikata T, Yamaoka-Tojo M, Namba S, Kitasato L, Kameda R, Murakami M, Niwano H, Shimohama T, Tojo T and Ako J: Rivaroxaban inhibits angiotensin II-induced activation in cultured mouse cardiac fibroblasts through the modulation of NF-κB pathway. Int Heart J. 56:544–550. 2015. View Article : Google Scholar
26	Wai-Hoe L, Wing-Seng L, Ismail Z and Lay-Harn G: SDS-PAGE-based quantitative assay for screening of kidney stone disease. Biol Proced Online. 11:145–160. 2009. View Article : Google Scholar : PubMed/NCBI
27	Samoš M, Bolek T, Ivanková J, Stančiaková L, Kovář F, Galajda P, Kubisz P, Staško J and Mokáň M: Heparin induced thrombocy-topenia presenting with deep venous thrombosis and pulmonary embolism successfully treated with rivaroxaban: Clinical case report and review of current experiences. J Cardiovasc Pharmacol. 68:391–394. 2016. View Article : Google Scholar
28	Dirani M, Nasreddine W, Abdulla F and Beydoun A: Seizure control and improvement of neurological dysfunction in Lafora disease with perampanel. Epilepsy Behav Case Rep. 2:164–166. 2014. View Article : Google Scholar
29	Massberg S, Gawaz M, Grüner S, Schulte V, Konrad I, Zohlnhöfer D, Heinzmann U and Nieswandt B: A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med. 197:41–49. 2003. View Article : Google Scholar : PubMed/NCBI
30	Nuutila J, Hohenthal U, Laitinen I, Kotilainen P, Rajamäki A, Nikoskelainen J and Lilius EM: Simultaneous quantitative analysis of FcgammaRI (CD64) expression on neutrophils and monocytes: A new, improved way to detect infections. J Immunol Methods. 328:189–200. 2007. View Article : Google Scholar : PubMed/NCBI
31	Chuchalin AG, Tseimakh IY, Momot AR, Mamaev AN, Karbyshev IA and Strozenko LA: Thrombogenic risk factors in patients with exacerbation of chronic obstructive pulmonary disease. Klin Med (Mosk). 93:18–23. 2015.In Russian.
32	Cheung YW, Middeldorp S, Prins MH, Pap AF, Lensing AW, Ten Cate-Hoek AJ, Villalta S, Milan M, Beyer-Westendorf J, Verhamme P, et al Einstein PTS Investigators Group: Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis. Thromb Haemost. 116:733–738. 2016. View Article : Google Scholar : PubMed/NCBI
33	Deitelzweig S, Laliberté F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J and Lefebvre P: Hospitalizations and other health care resource utilization among patients with deep vein thrombosis treated with rivaroxaban versus low-molecular-weight heparin and warfarin in the outpatient setting. Clin Ther. 38:1803–1816.e1803. 2016. View Article : Google Scholar : PubMed/NCBI
34	Wan H, Yang Y, Zhu J, Wu S, Zhou Z, Huang B, Wang J, Shao X and Zhang H: An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: A comparison of dabigatran and rivaroxaban. Blood Coagul Fibrinolysis. 27:882–885. 2016. View Article : Google Scholar : PubMed/NCBI
35	Shlebak A: Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: A case series and a review. J Clin Pathol. 69:337–343. 2016. View Article : Google Scholar
36	Blum A and Shamburek R: The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis. Atherosclerosis. 203:325–330. 2009. View Article : Google Scholar
37	Lee KW, Blann AD and Lip GY: Plasma markers of endothelial damage/dysfunction, inflammation and thrombogenesis in relation to TIMI risk stratification in acute coronary syndromes. Thromb Haemost. 94:1077–1083. 2005.PubMed/NCBI
38	Terry CM, He Y and Cheung AK: Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis. Thromb Res. 144:106–112. 2016. View Article : Google Scholar : PubMed/NCBI
39	Shah PK: Thrombogenic risk factors for atherothrombosis. Rev Cardiovasc Med. 7:10–16. 2006.PubMed/NCBI
40	Chu NF, Spiegelman D, Hotamisligil GS, Rifai N, Stampfer M and Rimm EB: Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis. 157:495–503. 2001. View Article : Google Scholar : PubMed/NCBI
41	Pacheco YM, Bermúdez B, López S, Abia R, Villar J and Muriana FJ: Ratio of oleic to palmitic acid is a dietary determinant of thrombogenic and fibrinolytic factors during the postprandial state in men. Am J Clin Nutr. 84:342–349. 2006.PubMed/NCBI
42	Hartweg J, Farmer AJ, Holman RR and Neil HA: Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. Diabetologia. 50:250–258. 2007. View Article : Google Scholar
43	Juhan-Vague I, Alessi MC and Vague P: Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med. 28:371–380. 1996. View Article : Google Scholar : PubMed/NCBI
44	Dewyer NA, Sood V, Lynch EM, Luke CE, Upchurch GR Jr, Wakefield TW, Kunkel S and Henke PK: Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution. J Surg Res. 142:357–363. 2007. View Article : Google Scholar : PubMed/NCBI
45	Nosaka M, Ishida Y, Kimura A and Kondo T: Immunohistochemical detection of MMP-2 and MMP-9 in a stasis-induced deep vein thrombosis model and its application to thrombus age estimation. Int J Legal Med. 124:439–444. 2010. View Article : Google Scholar : PubMed/NCBI
46	Malaponte G, Polesel J, Candido S, Sambataro D, Bevelacqua V, Anzaldi M, Vella N, Fiore V, Militello L, Mazzarino MC, et al: IL-6-174 G>C and MMP-9-1562 C>T polymorphisms are associated with increased risk of deep vein thrombosis in cancer patients. Cytokine. 62:64–69. 2013. View Article : Google Scholar : PubMed/NCBI
47	Bhaskar S, Sudhakaran PR and Helen A: Quercetin attenuates atherosclerotic inflammation and adhesion molecule expression by modulating TLR-NF-κB signaling pathway. Cell Immunol. 310:131–140. 2016. View Article : Google Scholar : PubMed/NCBI
48	García-Trapero J, Carceller F, Dujovny M and Cuevas P: Perivascular delivery of neomycin inhibits the activation of NF-kappaB and MAPK pathways, and prevents neointimal hyperplasia and stenosis after arterial injury. Neurol Res. 26:816–824. 2004. View Article : Google Scholar
49	Gao MY, Chen L, Yang L, Yu X, Kou JP and Yu BY: Berberine inhibits LPS-induced TF procoagulant activity and expression through NF-κB/p65 Akt and MAPK pathway in THP-1 cells. Pharmacol Rep. 66:480–484. 2014. View Article : Google Scholar : PubMed/NCBI